Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock

Cameron Turtle, Chief Executive Officer and a Director at Spyre Therapeutics, Inc. (NASDAQ:SYRE), sold 14,000 shares of the company’s common stock on October 1, 2026. The transactions totaled approximately $1,380,104, with shares sold at weighted average prices ranging from $89.14 to $93.91. The sale comes after the stock has surged 487% over the past year, though InvestingPro analysis indicates the shares are currently overvalued relative to its Fair Value estimate. Investors can explore more overvalued stocks on the Most Overvalued list.

These sales were executed under a Rule 10b5-1 trading plan, which Mr. Turtle adopted on June 20, 2025. Following these transactions, Mr. Turtle beneficially owns 537,540 shares of Spyre Therapeutics common stock. This total includes 29,078 shares that are subject to monthly vesting through November 2026, contingent on Mr. Turtle’s continued service to the company. The company is not currently profitable, with analysts forecasting it will remain unprofitable this year—one of 13 InvestingPro Tips available for SYRE subscribers.

In other recent news, Spyre Therapeutics announced the topline results from its Phase II SKYWAY-RA program, revealing that SPY072/TL1A showed statistically significant or numerically greater efficacy improvement over placebo in rheumatoid arthritis patients. However, the magnitude of the effect did not meet the company’s internal threshold for prioritizing monotherapy development, leading to a notable decline in the stock. Despite this, Stifel reiterated a Buy rating with a $123.00 price target, noting that the study achieved statistical significance on some endpoints and doses. Similarly, Guggenheim maintained a Buy rating with a $130 price target, emphasizing Spyre’s focus on inflammatory bowel disease (IBD).

JPMorgan initiated coverage on Spyre with an Overweight rating and a $110.00 price target, highlighting the company’s competitive Phase 2 data in its IBD pipeline. Baird also reiterated an Outperform rating with a $116.00 price target, citing positive results from the SPY003 trial in ulcerative colitis. These developments underscore the mixed reactions from analysts, with a focus on Spyre’s clinical-stage assets targeting conditions like ulcerative colitis and rheumatoid arthritis.